Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)
- Home
- Long-Acting Injectable Antipsychotics & The Evolving Healthcare Landscape Post-COVID-19 Pandemic For Patients With Schizophrenia & Bipolar I Disorder
- Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)
In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.